miRNA-574-5p Biomarker for NSCLC Prostaglandin E Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to effectively stratify non-small cell lung cancer (NSCLC) tumors for response to therapeutic drugs such as NSAIDs or PEG synthase inhibitors, leading to variability in treatment outcomes.
Innovation Solution
A method involving the determination of miRNA-574-5p levels in test samples, comparison to a reference, and identification of subjects susceptible to prostaglandin E formation inhibitors, utilizing specific detection agents and automated processes for accurate stratification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used for treating NSCLC with NSAIDs or PEG synthase inhibitors, then treatment is administered to patients, but variability in treatment response occurs due to inability to stratify tumors
Solution Approach 1:
The patent replaces complex pathological and molecular analysis systems with a simple miRNA-574-5p detection system. Instead of using complex methods to analyze COX-2 and mPGES-1 expression levels and their interactions, the invention uses a single miRNA biomarker that can be detected through relatively simple molecular biology techniques, thereby reducing system complexity while maintaining or improving stratification accuracy
Solution Approach 2:
The patent changes the parameter used for tumor stratification from complex multi-gene expression profiles (COX-2, mPGES-1) to a single miRNA expression level (miRNA-574-5p). This parameter simplification allows for easier measurement and comparison, improving the reliability of treatment response prediction without requiring complex analytical systems
2Measurement precision
If miRNA-574-5p determination and comparison method is implemented, then accurate identification of susceptible subjects is achieved, but additional testing steps and time are required
Solution Approach 1:
The patent extracts the essential information needed for susceptibility identification from complex multi-gene profiles and isolates it into a single miRNA-574-5p biomarker. By taking out only the critical predictive element rather than analyzing the entire complex molecular profile, the method achieves high measurement precision while minimizing the time and resources required for testing
Data Source
Figure 1a~1f
Figure 2a~2i
Figure 3a~3e
AI summary
The present invention relates to the field of diagnostic methods. More specifically, it relates to a method for identifying a subject suffering from a prostaglandin E-dependent tumor as being susceptible to a therapy with an inhibitor of prostaglandin E formation comprising the steps of determining in a test sample of the subject the amount of microRNA-574-5p, comparing the determined amount to a reference, and identifying a subject suffering from a prostaglandin E- dependent tumor as being susceptible to a therapy with an inhibitor of prostaglandin E formation based on said comparison. Moreover, the invention also encompasses the use of microRNA-574-5p or a detection agent that specifically binds thereto in a sample of a subject suffering from a prostaglandin E-dependent tumor for identifying the subject as being susceptible to a therapy with an inhibitor of prostaglandin E formation and a device as well as a kit for carrying out the method of the invention.